IP Verse

Compounds For Improved Viral Transduction - EP2760994

The patent EP2760994 was granted to Bluebird BIO on Sep 15, 2021. The application was originally filed on Sep 28, 2012 under application number EP12836507A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2760994

BLUEBIRD BIO
Application Number
EP12836507A
Filing Date
Sep 28, 2012
Status
Patent Maintained As Amended
Aug 13, 2021
Grant Date
Sep 15, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SAGITTARIUSFeb 28, 2018HGFADMISSIBLE
MULLER FOTTNER STEINECKE RECHTSANWALTS UND PATENTANWALTSPARTNERSCHAFT MBBFeb 27, 2018WITTHOFF JAEKEL STEINECKE PATENTANWALTE PARTG MBBWITHDRAWN

Patent Citations (43) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2006247214
DESCRIPTIONUS4873192
DESCRIPTIONUS5223409
DESCRIPTIONUS5399363
DESCRIPTIONUS5466468
DESCRIPTIONUS5543158
DESCRIPTIONUS5641515
DESCRIPTIONUS5725871
DESCRIPTIONUS5756353
DESCRIPTIONUS5780045
DESCRIPTIONUS5804212
DESCRIPTIONUS5861488
DESCRIPTIONUS5864029
DESCRIPTIONUS5869039
DESCRIPTIONUS5877288
DESCRIPTIONUS5994136
DESCRIPTIONUS6013516
DESCRIPTIONUS6013769
DESCRIPTIONUS6051402
DESCRIPTIONUS6057117
DESCRIPTIONUS6608063
DESCRIPTIONUS6610719
DESCRIPTIONUS6670323
DESCRIPTIONUS6682907
DESCRIPTIONUS6747037
DESCRIPTIONUS7901671
DESCRIPTIONWO0038663
DESCRIPTIONWO0112596
DESCRIPTIONWO02088346
DESCRIPTIONWO2006047476
DESCRIPTIONWO2007071456
DESCRIPTIONWO2007112084
DESCRIPTIONWO2008108741
DESCRIPTIONWO2008126932
DESCRIPTIONWO2010108028
INTERNATIONAL-SEARCH-REPORTUS2009092589
INTERNATIONAL-SEARCH-REPORTWO2010054271
OPPOSITIONWO2004098531
OPPOSITIONWO2007112084
OPPOSITIONWO2010054271
OPPOSITIONWO2013049615
OPPOSITIONWO9800541
SEARCHWO2004098531

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- PAWLIUK R ET AL, "Correction of sickle cell disease in transgenic mouse models of gene therapy", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, (20011214), vol. 294, doi:10.1126/SCIENCE.1065806, ISSN 0036-8075, pages 2368 - 2371, XP002984304
EXAMINATION- N. Cartier ET AL, "Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy", Science, US, (20091106), vol. 326, no. 5954, doi:10.1126/science.1171242, ISSN 0036-8075, pages 818 - 823, XP055268270
EXAMINATION- G. Puthenveetil ET AL, "Successful correction of the human  -thalassemia major phenotype using a lentiviral vector", Blood, (20041201), vol. 104, no. 12, doi:10.1182/blood-2004-04-1427, ISSN 0006-4971, pages 3445 - 3453, XP055216529
OPPOSITION- Anonymous, "Technical Resources 12440 - IMDM", ThermoFischer Scientific, URL: https://www.thermofisher.com/uk/en/home/technical-resources/media-formulation.76.html-
OPPOSITION- BUCZYNSKI M W et al., Journal of lipid research, (20090000), vol. 50, pages 1015 - 1038, XP055470884-
OPPOSITION- ROBERSTON et al., "Thromboxane A2 in Vasotonic Angina Pectoris — Evidence from Direct Measurements and Inhibitor Trials", New England Journal of Medicine, (19810000), vol. 304, no. 17, pages 998 - 1003, XP055632981-
OPPOSITION- Ryuji Ueno, Sachiko Kuno, Osamu Hayaishi, "Possible Pathogenesis of Acquired Immune Deficiency Syndrome in Homosexual Males: An Unexpected Action of Seminal Prostaglandin E2 on AIDS-Virus Infection", Advances in Prostaglandin , Thromboxane and Leukotriene Research, (19870000), vol. 17, pages 151 - 154, XP055632959-
OPPOSITION- SUTTON R.E, "TRANSDUCTION OF HUMAN PROGENITOR HEMATOPOIETIC STEM CELLS BY HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-BASED VECTORS IS CELL CYCLE DEPENDENT", J. of Virol., (19990000), vol. 73, no. 5, pages 3649 - 3660, XP002937676-
OPPOSITION- NGUYEN et al., "Highly Efficient Lentiviral Vector-Mediated Transduction of Nondividing, fully Reimplantable Primary Hepatocytes", Molecular Therapy, (20020000), vol. 6, no. 2, pages 199 - 209, XP055632975
OPPOSITION- GOESSLING et al., "Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models", Cell Stem Cell, (20110000), vol. 8, no. 4, pages 445 - 458, XP055002056
OPPOSITION- Wolfram Goessling, et al.,, "Prostaglandin E2 Enhances Human Cord Blood Stem Cell Xenotransplants and Shows Long-Term Safety in Preclinical Nonhuman Primate Transplant Models /Supplemental Information /", vol. 8, (2011), pages 1 - 16, URL: https://www.cell.com/cms/10.1016/j.stem.2011.02.003/attachment/3cb20ce9-9ebe-4c93-8660-1c1828904c6f/mmc1.pdf, XP055632946
OPPOSITION- MOSTOSLAVSKY et al., "Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation", Molecular Therapy, (20050000), vol. 11, no. 6, pages 932 - 940, XP004908871
OPPOSITION- MOSTOSLAVSKY et al., "Molecular therapyEfficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation", Molecular therapy, (20050000), vol. 11, no. 6, pages 932 - 940, XP004908871
OPPOSITION- EVERS R, "Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1", FEBS Letters, (19970000), vol. 419, no. 1, pages 112 - 116, XP004261601
OPPOSITION- PAUMI C M, "Multidrug Resistance Protein (MRP) 1 and MRP3 Attenuate Cytotoxic and Transactivating Effects of the Cyclopentenone Prostaglandin", Biochemistry, (20030000), vol. 42, no. 18, pages 5429 - 5437, XP055470867
OPPOSITION- FOLLENZI et al., "Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences", Nature Genetics, (20000000), vol. 25, no. 2, pages 217 - 222, XP002980776
OPPOSITION- UCHIDA et al., "Optimal conditions for lentiviral transduction of engrafting human CD34+ cells", Gene Therapy., (20110000), vol. 18, pages 1078 - 1086, XP055206476
OPPOSITION- CASE et al., "STABLE TRANSDUCTION OF QUIESCENT CD34+CD38- HUMAN HEMATOPOIETIC CELLS BY HIV-1 BASED LENTIVIRAL VECTORS", Proc. Natl. Acad. Sci. USA, (19990000), vol. 96, pages 2988 - 2993, XP000879829
OPPOSITION- SUGIMOTO Y, "Prostaglandin E receptors", Journal of Biological Chemistry, (20070000), vol. 282, no. 16, pages 11613 - 11617, XP002579966
OPPOSITION- DEMAISON et al., "High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter", Human Gene Therapy, (20020000), vol. 13, no. 7, pages 803 - 813, XP002263326
OPPOSITION- WAART et al., "Multidrug resistance associated protein 2 mediates transport of prostaglandin E2", Liver International, (20060000), vol. 26, pages 362 - 2368, XP055632966
SEARCH- MOSTOSLAVSKY ET AL, "Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, (20050601), vol. 11, no. 6, doi:10.1016/J.YMTHE.2005.01.005, ISSN 1525-0016, pages 932 - 940, XP005002713 [I] 1-15 * figure 1c *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents